| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Alfredo Di Leo | |
| Mariabeatrice Principi | |||
| Enzo Ierardi | |||
| Giuseppe Losurdo | |||
| Roberto Bringiotti | |||
| Rosa Lovero | |||
| P2860 | cites work | Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection | Q79502910 |
| Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy | Q81244404 | ||
| Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis | Q83333118 | ||
| Genes in inflammatory bowel disease: lessons from complex diseases | Q83613913 | ||
| Probiotics and inflammatory bowel diseases | Q83929578 | ||
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
| Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report | Q88139719 | ||
| Development of the human infant intestinal microbiota | Q21003936 | ||
| Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans | Q21133618 | ||
| Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee | Q22242348 | ||
| Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 | ||
| Probiotics for induction of remission in Crohn's disease | Q24242115 | ||
| Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice | Q24523182 | ||
| Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis | Q24537963 | ||
| A human gut microbial gene catalogue established by metagenomic sequencing | Q24618931 | ||
| Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region | Q24657139 | ||
| Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial | Q24685494 | ||
| Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps | Q27006760 | ||
| Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases | Q28131810 | ||
| Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis | Q28184074 | ||
| Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial | Q28213579 | ||
| Fecal microbiota transplantation and emerging applications | Q28255756 | ||
| A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result | Q28260707 | ||
| The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat | Q28263005 | ||
| Smoking and inflammatory bowel disease: a meta-analysis | Q28275088 | ||
| Ecological and evolutionary forces shaping microbial diversity in the human intestine | Q29547586 | ||
| Microbial influences in inflammatory bowel diseases | Q29614264 | ||
| NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation | Q29615617 | ||
| Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry | Q29615618 | ||
| Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences | Q29617565 | ||
| The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota | Q29619977 | ||
| Is meconium from healthy newborns actually sterile? | Q30841114 | ||
| Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease | Q33201542 | ||
| Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats | Q33515113 | ||
| Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) | Q33557634 | ||
| Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism | Q33767365 | ||
| Dietary carbohydrates and the colonic microflora | Q33775410 | ||
| Dietary resistant starch and chronic inflammatory bowel diseases | Q33824481 | ||
| Impact of cessation of smoking on the course of ulcerative colitis | Q33953697 | ||
| Management of Crohn's disease in smokers: is an alternative approach necessary? | Q34028909 | ||
| Crohn disease: a current perspective on genetics, autophagy and immunity | Q34132601 | ||
| The gut microbiota elicits a profound metabolic reorientation in the mouse jejunal mucosa during conventionalisation | Q34313357 | ||
| Double blind, placebo controlled trial of metronidazole in Crohn's disease | Q34394436 | ||
| Smoking in Crohn's disease: effect on localisation and clinical course | Q34395435 | ||
| Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial | Q34410821 | ||
| Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells | Q47945739 | ||
| A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. | Q50968026 | ||
| Effects of cigarette smoking on the long-term course of Crohn's disease. | Q51041452 | ||
| Open label trial of oral clarithromycin in active Crohn's disease. | Q53910434 | ||
| Lactoferrin prevents invasion and inflammatory response following E. coli strain LF82 infection in experimental model of Crohn's disease. | Q54293140 | ||
| Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. | Q54488011 | ||
| An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. | Q54727809 | ||
| Antiinflammatory Effects of Enterically Coated Amoxicillin-Clavulanic Acid in Active Ulcerative Colitis | Q57241203 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Effect of inflammatory bowel disease classification changes on NOD2 genotype–phenotype associations in a population-based cohort | Q60630413 | ||
| Colonic mucins in ulcerative colitis: evidence for loss of sulfation | Q71762357 | ||
| Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection | Q72281835 | ||
| Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? | Q74126152 | ||
| Combination ciprofloxacin and metronidazole for active Crohn's disease | Q74448843 | ||
| A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) | Q74623807 | ||
| Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice | Q77659986 | ||
| Long-term treatment of ulcerative colitis with ciprofloxacin | Q78068816 | ||
| Epidemiology of inflammatory bowel disease | Q79221403 | ||
| Starches, resistant starches, the gut microflora and human health. | Q34440259 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease | Q34529230 | ||
| Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients | Q34580564 | ||
| Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection | Q34633079 | ||
| Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota | Q34778107 | ||
| Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? | Q35165249 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease | Q35760252 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics | Q35787456 | ||
| Bacterial diversity in the human gut. | Q35835077 | ||
| High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease | Q35929551 | ||
| Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice | Q36087089 | ||
| NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. | Q36580437 | ||
| Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases | Q36973376 | ||
| Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. | Q37178680 | ||
| CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease | Q37216685 | ||
| Establishment of the gut microbiota in Western infants. | Q37368368 | ||
| Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice | Q37394024 | ||
| High-fat diet determines the composition of the murine gut microbiome independently of obesity | Q37404989 | ||
| Review article: faecal transplantation therapy for gastrointestinal disease | Q37891143 | ||
| Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease | Q38029111 | ||
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management | Q38049776 | ||
| Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. | Q39830081 | ||
| Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats | Q40833729 | ||
| Preliminary study of ciprofloxacin in active Crohn's disease | Q42169291 | ||
| Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment | Q43005855 | ||
| Effects of probiotic on intestinal mucosa of patients with ulcerative colitis | Q43159889 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Mucosal flora in inflammatory bowel disease | Q43503928 | ||
| Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. | Q43618399 | ||
| A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis | Q43807182 | ||
| Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis | Q43988863 | ||
| Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. | Q44629149 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing | Q45251378 | ||
| Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis | Q45285907 | ||
| What are the consequences of the disappearing human microbiota? | Q47429245 | ||
| P433 | issue | 4 | |
| P921 | main subject | inflammation | Q101991 |
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 550-559 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | World journal of gastrointestinal pathophysiology | Q27723538 |
| P1476 | title | Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? | |
| P478 | volume | 5 |
| Q47423017 | A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information |
| Q26777641 | Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? |
| Q38507612 | Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature |
| Q28076892 | Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article |
| Q34521876 | Current Understanding of Dysbiosis in Disease in Human and Animal Models |
| Q36553757 | Estrogen receptor beta as target for colorectal cancer prevention |
| Q36050474 | Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis |
| Q53170686 | Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. |
| Q26745455 | Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association |
| Q39445579 | INTESTINAL MICROBIOTA IN DIGESTIVE DISEASES. |
| Q57816699 | Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages |
| Q37092839 | Immunomodulatory Effects of Lactobacillus plantarum Lp62 on Intestinal Epithelial and Mononuclear Cells |
| Q39630894 | Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. |
| Q38970266 | Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario |
| Q41128408 | May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? |
| Q48171878 | Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. |
| Q26777414 | Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease |
| Q38461139 | Products for the treatment of inflammatory bowel disease: a patent review (2013 - 2014). |
| Q35730471 | Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. |
| Q36063411 | Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy |
| Q42921978 | The Changing Face of Very Early-Onset Inflammatory Bowel Disease |
| Q26795705 | The Intestinal Microbiota in Inflammatory Bowel Disease |
| Q36159700 | The dual role of Escherichia coli in the course of ulcerative colitis |
Search more.